PTG 630
Alternative Names: PTG-630Latest Information Update: 11 Apr 2023
Price :
$50 *
At a glance
- Originator Praetego
- Class Small molecules
- Mechanism of Action Advanced glycosylation end product inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Diabetic neuropathies
- Research Diabetic retinopathy
Most Recent Events
- 11 Apr 2023 Early research in Diabetic retinopathy in USA (unspecified route) (Praetego pipeline, April 2023)
- 05 Oct 2022 Praetego plans to files an IND application for Alzheimer's Disease in December 2023
- 04 Oct 2022 Preclinical trials in Alzheimer's disease in USA (unspecified route) (Praetego company pipeline October 2022)